专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240392279A1 MODIFIED PROTEIN DISULFIDE ISOMERASE AND USES THEREOF 审中-公开
公开(公告)号：US20240392279A1
公开(公告)日：2024-11-28
申请号：US18691748
申请日：2022-09-16
申请人： The University of North Carolina at Chapel Hill
发明人： Baggio Evangelista , Todd Cohen
IPC分类号： C12N9/90 , A61P3/00
CPC分类号： C12N9/90 , A61P3/00 , C12Y503/04001
摘要： Disclosed herein are modified protein disulfide isomerases (PDIs) or functional fragments thereof wherein the modified PDI or functional fragment thereof comprises a deletion of an endoplasmic reticulum (ER) signal sequence from a wild-type PDI or functional fragments thereof, and methods of making and using the same. The modified PDI or functional fragment thereof may be used to treat diseases associated with protein aggregates, including neurodegenerative diseases, muscular diseases, injuries, and aging-related conditions.

2. 发明授权

US12011476B2 Treatments of oxidative stress conditions 有权
公开(公告)号：US12011476B2
公开(公告)日：2024-06-18
申请号：US15931809
申请日：2020-05-14
申请人： The University of Vermont and State Agricultural College
发明人： Yvonne M. Janssen-Heininger , Vikas Anathy
IPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/16 , A61K38/45 , A61K45/06 , C12N15/113
CPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/164 , A61K38/45 , A61K45/06 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y205/01018 , C12Y503/04001 , A61K31/425 , A61K2300/00 , A61K31/437 , A61K2300/00
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

5. 发明授权

US10612063B2 Methods and strains for producing bioproducts in 有权
公开(公告)号：US10612063B2
公开(公告)日：2020-04-07
申请号：US16406161
申请日：2019-05-08
申请人： The United States of America, as represented by the Secretary of Agriculture
发明人： Christopher D. Skory , Timothy D. Leathers , Neil P. Price
IPC分类号： C12N9/10 , C12P7/64 , C12P19/10 , C12N1/14 , C07H21/04 , C12P19/24 , C12P17/06 , C12N9/04 , C12N9/90 , C12N9/12 , C12P19/02 , C12N1/16 , C12N9/00 , C12N15/52 , C12P7/62 , C12P17/02 , C12P19/44 , C12P21/02
CPC分类号： C12P19/24 , C12N1/16 , C12N9/00 , C12N9/0006 , C12N9/1029 , C12N9/1205 , C12N9/90 , C12N15/52 , C12P7/62 , C12P7/64 , C12P7/6409 , C12P7/6436 , C12P17/02 , C12P17/06 , C12P19/02 , C12P19/10 , C12P19/44 , C12P21/02 , C12Y101/01037 , C12Y207/01037 , C12Y503/04001
摘要： The present disclosure provides methods for producing bioproducts from novel genetically altered strains of Aureobasidium pullulans. Methods and materials for the construction of these strains, examination of the bioproducts and analysis and isolation of the bioproducts from genetically altered strains is provided. Genetically altered A. pullulans strains in which one or more genes encoding biosynthetic enzymes are knocked out is detailed and the benefits of using such strains described.

6. 发明申请

US20190210323A1 A METHOD OF PRODUCING A MINERAL WOOL PRODUCT COMPRISING A MULTIPLE OF LAMELLAE AND A PRODUCT OF SUCH KIND 审中-公开
公开(公告)号：US20190210323A1
公开(公告)日：2019-07-11
申请号：US16301232
申请日：2017-05-11
申请人： Rockwool International A/S
发明人： Thomas Hjelmgaard , Oskar Meres , Bent Jacobsen
IPC分类号： B32B7/12 , C03C25/328 , B32B19/04 , B32B37/12 , B32B37/18 , B32B38/00 , C03C25/321 , D04H1/4209 , D04H1/593 , D04H1/74 , C09J5/00 , C09J189/06 , C09J101/28 , C09J103/02 , E04C2/284 , E04F13/08 , E04D3/35 , E04B1/80
CPC分类号： D04H1/587 , B32B7/12 , B32B19/04 , B32B37/12 , B32B37/18 , B32B38/0004 , B32B2037/1253 , B32B2250/20 , B32B2255/02 , B32B2255/26 , B32B2307/304 , B32B2315/14 , B32B2607/00 , C03C25/26 , C03C25/32 , C03C25/321 , C03C25/328 , C08L5/12 , C08L89/06 , C09J5/00 , C09J11/06 , C09J101/28 , C09J101/286 , C09J103/02 , C09J105/00 , C09J105/04 , C09J105/06 , C09J105/12 , C09J189/005 , C09J189/06 , C09J2401/00 , C09J2403/00 , C09J2405/00 , C09J2489/00 , C12Y104/03013 , C12Y108/03002 , C12Y111/01007 , C12Y114/18001 , C12Y203/02013 , C12Y503/04001 , D04H1/4209 , D04H1/4218 , D04H1/4266 , D04H1/593 , D04H1/724 , D04H1/74 , D10B2505/20 , E04B1/74 , E04B1/80 , E04B2001/743 , E04B2001/745 , E04B2001/7683 , E04C2/284 , E04D3/352 , E04F13/0866
摘要： A method and a mineral wool product include a multiple of lamellae, such as a sandwich panel core. The product includes a plurality of lamellae cut from a mineral wool web, and bonded together by applying an adhesive on the surfaces of two adjacent lamellae to form a web-like product, wherein the adhesive comprises at least one hydrocolloid.

7. 发明申请

US20180179545A1 REDUCTION OF LIPASE ACTIVITY IN PRODUCT FORMULATIONS 审中-公开
公开(公告)号：US20180179545A1
公开(公告)日：2018-06-28
申请号：US15897290
申请日：2018-02-15
申请人： Kelvin LEE , Abraham Lenhoff , Kristin Valente , Nick Levy , Yatin Gokarn
发明人： Kelvin LEE , Abraham Lenhoff , Kristin Valente , Nick Levy , Yatin Gokarn
IPC分类号： C12N15/113 , C07K16/00 , A61K38/17 , A61K38/39 , A61K38/42 , A61K38/44 , A61K38/45 , A61K38/48 , A61K38/52 , A61K47/26 , C12P21/00 , C12N9/20 , C12P21/02
CPC分类号： C12N15/1137 , A61K38/1709 , A61K38/1741 , A61K38/1761 , A61K38/1774 , A61K38/39 , A61K38/42 , A61K38/44 , A61K38/443 , A61K38/45 , A61K38/4813 , A61K38/482 , A61K38/488 , A61K38/52 , A61K47/26 , C07K16/00 , C12N9/20 , C12N2310/10 , C12N2310/14 , C12N2310/20 , C12P21/005 , C12P21/02 , C12Y104/03013 , C12Y111/01015 , C12Y205/01018 , C12Y207/04006 , C12Y207/11001 , C12Y301/01034 , C12Y304/16005 , C12Y304/21 , C12Y304/23005 , C12Y502/01008 , C12Y503/04001
摘要： The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.

8. 发明授权

US09588119B2 In vitro method of inhibiting the growth of radioresistant laryngeal cancer cells 有权
标题翻译：抑制放射抗性喉癌细胞生长的体外方法
公开(公告)号：US09588119B2
公开(公告)日：2017-03-07
申请号：US14746859
申请日：2015-06-23
申请人： KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
发明人： Jae-Sung Kim , Sang-Gu Hwang , Young-Hoon Han
IPC分类号： G01N33/574 , C12N15/113
CPC分类号： G01N33/57407 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y503/04001 , G01N33/5011 , G01N2333/99
摘要： Disclosed are increased expression of ERp57, ERp57-STAT3 complex, and ERp57-STAT3-Mcl-1 in laryngeal cancer, especially in radioresistant laryngeal cancer and their regulations on radioresistance of laryngeal cancer. As such, the efficacy of radiotherapy can be enhanced by diagnosing prognosis in laryngeal cancer and radioresistance of laryngeal cancer. Furthermore, provided are a method of screening a therapeutic agent for laryngeal cancer including selecting a candidate drug that inhibits the expression of ERp57 or inactivates ERp57, and a therapeutic method for inhibiting or treating laryngeal cancer or radioresistant laryngeal cancer, thereby being useful in the treatment of laryngeal cancer.
摘要翻译：公开了喉癌中ERp57，ERp57-STAT3复合物和ERp57-STAT3-Mcl-1的表达增加，特别是放射抗性喉癌及其对喉癌放射线抗性的调节。因此，可以通过诊断喉癌的预后和喉癌的放射线抗性来增强放射治疗的疗效。此外，提供筛选喉癌治疗剂的方法，包括选择抑制ERp57表达或使ERp57失活的候选药物，以及用于抑制或治疗喉癌或放射线阻断性喉癌的治疗方法，从而可用于治疗的喉癌。

9. 发明授权

US09265786B1 Method for reducing protein misfolding and accumulation in Huntington'S disease cells 有权
标题翻译：减少亨廷顿病细胞中蛋白质错误折叠和积聚的方法
公开(公告)号：US09265786B1
公开(公告)日：2016-02-23
申请号：US13854809
申请日：2013-04-01
申请人： University of Wyoming
发明人： Jonathan H. Fox
IPC分类号： A61K48/00 , A01N63/00 , A61K31/711
CPC分类号： A61K31/711 , A61K48/005 , C12N9/0036 , C12N9/90 , C12N15/86 , C12N2740/16043 , C12Y503/04001
摘要： A method and virus for decreasing the levels of the disease-causing protein in Huntington's disease (mhtt) are described. Increased expression of human TXNDC10, and TXN1 in diseased cells decreases levels of toxic mhtt in cell models of disease. Genetically increasing the expression of the genes producing these proteins using viral vectors, or small molecule chemical activators of gene expression or stimulators of enzymatic activity, may be used to treat Huntington's disease in the asymptomatic carrier or affected human. Since other protein misfolding neurodegenerative diseases have many features in common with Huntington's disease, including the structure of the misfolded protein, the present method may be applicable to other protein misfolding neurodegenerative diseases.
摘要翻译：描述了用于降低亨廷顿氏病（mhtt）中引起疾病的蛋白质的水平的方法和病毒。人类TXNDC10和TXN1在患病细胞中的表达增加可以降低疾病细胞模型中毒性mhtt的水平。使用病毒载体或基因表达的小分子化学活化剂或酶活性刺激剂基因上增加产生这些蛋白质的基因的表达，可用于在无症状的载体或受影响的人中治疗亨廷顿舞蹈病。由于其他蛋白质错误折叠的神经变性疾病具有许多与亨廷顿疾病相关的特征，包括错误折叠的蛋白质的结构，本方法可适用于其他蛋白质错误折叠的神经变性疾病。

10. 发明申请

US20080199496A1 Genes Associated with Leishmania Parasite Virulence 失效
标题翻译：与利什曼原虫寄生虫毒力相关的基因
公开(公告)号：US20080199496A1
公开(公告)日：2008-08-21
申请号：US12056764
申请日：2008-03-27
申请人： Yosser Ben Achour , Mehdi Chenik , Hechmi Louzir , Koussay Dellagi
发明人： Yosser Ben Achour , Mehdi Chenik , Hechmi Louzir , Koussay Dellagi
IPC分类号： C12N9/90 , C12N15/52 , C12N1/21 , C07H21/00 , A61K38/52 , A61K31/7088 , A61K35/74 , A61K35/68 , C07K14/44 , A61K38/12 , G01N33/53 , C07K16/00
CPC分类号： C12Y503/04001 , C07H21/04 , C07K2319/00 , C12N9/90 , Y02A50/41
摘要： The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
摘要翻译：本发明涉及打击利什曼病的领域。所述发明的结果是从利什曼原虫的野生分离物中分离出称为LmPDI的蛋白质编码基因，其具有与蛋白质的潜在活性位点的序列（Cys-Gly-His-Cys）相同的两个区域二硫化异构酶（PDI）。 LmPDI蛋白主要在寄生虫的最强毒株中表达。所述蛋白质形成用于开发抗利什曼病药物的新型治疗靶标和可用于免疫原性和可能接种疫苗的制剂的组合物的新颖元件，其旨在保护人或动物宿主免受利什曼原虫（Leishmania）的侵害。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式